Final 5‐Year Report of the Randomized BIO‐RESORT Trial Comparing 3 Contemporary Drug‐Eluting Stents in All‐Comers
Eline H. Ploumen,Tineke H. Pinxterhuis,Rosaly A. Buiten,Paolo Zocca,Peter W. Danse,Carl E. Schotborgh,Martijn Scholte,R. Melvyn Tjon Joe Gin,Samer Somi,K. Gert van Houwelingen,Martin G. Stoel,H. A. F. de Man,Marc Hartmann,Gerard C. M. Linssen,Liefke C. van der Heijden,Carine J. M. Doggen,Clemens von Birgelen,Marlies M. Kok
DOI: https://doi.org/10.1161/JAHA.122.026041
2022-11-09
Abstract:Background In a previous trial, higher 5‐year mortality was observed following treatment with biodegradable polymer Orsiro sirolimus‐eluting stents (SES). We assessed 5‐year safety and efficacy of all‐comers as well as patients with diabetes treated with SES or Synergy everolimus‐eluting stents (EES) versus durable polymer Resolute Integrity zotarolimus‐eluting stents (ZES). Methods and Results The randomized BIO‐RESORT (Comparison of Biodegradable Polymer and Durable Polymer Drug‐Eluting Stents in an All Comers Population) trial enrolled 3514 all‐comer patients at 4 Dutch cardiac centers. Patients aged ≥18 years who required percutaneous coronary intervention were eligible. Participants were stratified for diabetes and randomized to treatment with SES, EES, or ZES (1:1:1). The main end point was target vessel failure (cardiac mortality, target vessel myocardial infarction, or target vessel revascularization). Five‐year follow‐up was available in 3183 of 3514 (90.6%) patients. The main end point target vessel failure occurred in 142 of 1169 (12.7%) patients treated with SES, 130 of 1172 (11.6%) treated with EES, versus 157 of 1173 (14.1%) treated with ZES (hazard ratio [HR], 0.89 [95% CI, 0.71–1.12], P log‐rank =0.31; and HR, 0.82 [95% CI, 0.65–1.04], P log‐rank =0.10, respectively). Individual components of target vessel failure showed no significant between‐stent difference. Very late definite stent thrombosis rates were low and similar (SES, 1.1%; EES, 0.6%; ZES, 0.9%). In patients with diabetes, target vessel failure did not differ significantly between stent‐groups (SES, 19.8%; EES, 19.2%; versus ZES, 21.1% [ P log‐rank =0.69 and P log‐rank =0.63]). Conclusions Orsiro SES, Synergy EES, and Resolute Integrity ZES showed similar 5‐year outcomes of safety and efficacy, including mortality. A prespecified stent comparison in patients with diabetes also revealed no significant differences in 5‐year clinical outcomes. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT01674803. Nonstandard Abbreviations and Acronyms BIOFLOW III BIOTRONIK—Safety and Performance Registry for an All‐comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice III BIO‐RESORT Comparison of Biodegradable Polymer and Durable Polymer Drug‐Eluting Stents in an All Comers Population BIOSCIENCE Ultrathin Strut Biodegradable Polymer Sirolimus‐Eluting Stent Versus Durable Polymer Everolimus‐Eluting Stent for Percutaneous Coronary Revascularization DES drug‐eluting stent DUTCH PEERS Third‐Generation Zotarolimus‐Eluting and Everolimus‐Eluting Stents in All‐Comer Patients Requiring a Percutaneous Coronary Intervention EES everolimus‐eluting stent EVOLVE II The EVOLVE II Clinical Trial to Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s) RESOLUTE US Clinical Evaluation of the Medtronic Resolute Zotarolimus‐Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2 mm SES sirolimus‐eluting stents ZES zotarolimus‐eluting stents Clinical Perspective What Is New? Between Orsiro and Resolute Integrity stents, we found no significant differences in safety and efficacy, including all‐cause mortality. This randomized study presents the first 5‐year follow‐up data of the biodegradable polymer Synergy stent, showing in all‐comer patients safety and efficacy similar to the durable polymer Resolute Integrity stent. What Are the Clinical Implications? All‐comer patients and patients with diabetes can be safely and effectively treated with Orsiro, Synergy, and Resolute Integrity drug‐eluting sten -Abstract Truncated-